NFL Biosciences: CESTO II trial progressing on schedule Read more about NFL Biosciences: CESTO II trial progressing on schedule
Significant growth in revenues in 2022 & successfull acquisitions integration Read more about Significant growth in revenues in 2022 & successfull acquisitions integration
2022 revenue: EUR 35.3 m - 2023 targets and perspectives Read more about 2022 revenue: EUR 35.3 m - 2023 targets and perspectives
2022 revenue: EUR 35.8 m - 2023 targets and perspectives Read more about 2022 revenue: EUR 35.8 m - 2023 targets and perspectives
Update on progress regarding Multi-Project-Wafer ("MPW") Read more about Update on progress regarding Multi-Project-Wafer ("MPW")
Havyard Leirvik win important contract with a new customer Read more about Havyard Leirvik win important contract with a new customer
Transactions made under the repurchase program for Eqva ASA Read more about Transactions made under the repurchase program for Eqva ASA